{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:45:31Z","timestamp":1792637131010,"version":"4.5.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1097\/aog.0b013e318220edcc","type":"journal-article","created":{"date-parts":[[2011,6,4]],"date-time":"2011-06-04T04:19:41Z","timestamp":1307161181000},"page":"111-120","source":"Crossref","is-referenced-by-count":174,"title":["Selective Serotonin Reuptake Inhibitors and Risk for Major Congenital Anomalies"],"prefix":"10.1097","volume":"118","author":[{"given":"Heli","family":"Malm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miia","family":"Artama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Gissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annukka","family":"Ritvanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210126","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.reprotox.2010.04.015","article-title":"Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs).","volume":"30","author":"Ellfolk","year":"2010","journal-title":"Reprod Toxicol"},{"key":"R2-16-20210126","first-page":"9","article-title":"Epidemiology of depression throughout the female life cycle.","volume":"63","author":"Burt","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R3-16-20210126","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajog.2007.07.036","article-title":"Use of antidepressant medications during pregnancy: a multisite study.","volume":"198","author":"Andrade","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R4-16-20210126","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4065\/84.1.23","article-title":"Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy.","volume":"84","author":"Wichman","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"R5-16-20210126","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2125.2008.03261.x","article-title":"Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study.","volume":"66","author":"Diav-Citrin","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R6-16-20210126","doi-asserted-by":"crossref","first-page":"b3569","DOI":"10.1136\/bmj.b3569","article-title":"Selective serotonin reup-take inhibitors in pregnancy and congenital malformations: population based cohort study.","volume":"339","author":"Pedersen","year":"2009","journal-title":"BMJ"},{"key":"R7-16-20210126","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1056\/NEJMoa066584","article-title":"Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects.","volume":"356","author":"Alwan","year":"2007","journal-title":"N Engl J Med"},{"key":"R8-16-20210126","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1056\/NEJMoa067407","article-title":"First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.","volume":"356","author":"Louik","year":"2007","journal-title":"N Engl J Med"},{"key":"R9-16-20210126","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/bdra.20641","article-title":"First trimester use of paroxetine and congenital heart defects: a population based case-control study.","volume":"88","author":"Bakker","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R10-16-20210126","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1017\/S0033291709992194","article-title":"Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data.","volume":"40","author":"Reis","year":"2010","journal-title":"Psychol Med"},{"key":"R11-16-20210126","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/bdra.20627","article-title":"First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies.","volume":"88","author":"Wurst","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R12-16-20210126","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.clinthera.2007.05.003","article-title":"Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors.","volume":"29","author":"Bar-Oz","year":"2007","journal-title":"Clin Ther"},{"key":"R13-16-20210126","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/pds.1463","article-title":"Paroxetine in the first trimester and the prevalence of congenital malformations.","volume":"16","author":"Cole","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R14-16-20210126","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.AOG.0000187302.61812.53","article-title":"Risks associated with selective serotonin reuptake inhibitors in pregnancy.","volume":"106","author":"Malm","year":"2005","journal-title":"Obstet Gynecol"},{"key":"R15-16-20210126","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/bdrb.20144","article-title":"Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and ben-zodiazepines using population-based health data.","volume":"83","author":"Oberlander","year":"2008","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"R16-16-20210126","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/bdra.20643","article-title":"Paroxetine exposure during pregnancy and the risk of cardiac malformations: what is the evidence?","volume":"88","author":"B\u00e9rard","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R17-16-20210126","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/070674370905400405","article-title":"Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study.","volume":"54","author":"Einarson","year":"2009","journal-title":"Can J Psychiatry"},{"key":"R18-16-20210126","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/bdra.20615","article-title":"Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur.","volume":"85","author":"Merlob","year":"2009","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R19-16-20210126","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1176\/appi.ajp.2007.07060879","article-title":"Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy.","volume":"165","author":"Einarson","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R20-16-20210126","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/bdrb.20099","article-title":"First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.","volume":"80","author":"B\u00e9rard","year":"2007","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"R21-16-20210126","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/pds.1462","article-title":"Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy.","volume":"16","author":"Davis","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R22-16-20210126","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/bdra.20327","article-title":"Maternal use of selective serotonin reuptake inhibitors in early pregnancy and infant congenital malformations.","volume":"79","author":"K\u00e4ll\u00e9n","year":"2007","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R23-16-20210126","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.ede.0000239581.76793.ae","article-title":"Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations.","volume":"17","author":"Wogelius","year":"2006","journal-title":"Epidemiology"},{"key":"R24-16-20210126","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s002280050664","article-title":"Delivery outcome after the use of antidepressants in early pregnancy.","volume":"55","author":"Ericson","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"R25-16-20210126","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJM199610033351402","article-title":"Birth outcomes in pregnant women taking fluoxetine.","volume":"335","author":"Chambers","year":"1996","journal-title":"N Engl J Med"},{"key":"R26-16-20210126","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1001\/jama.1993.03500170076037","article-title":"Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac).","volume":"269","author":"Pastuszak","year":"1993","journal-title":"JAMA"},{"key":"R27-16-20210126","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/140349489502300113","article-title":"Data quality after restructuring a nationwide medical birth registry.","volume":"23","author":"Gissler","year":"1995","journal-title":"Scand J Soc Med"},{"key":"R30-16-20210126","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1002\/ajmg.a.31381","article-title":"Lethal congenital contracture syndrome (LCCS) and other lethal arthrogryposes in Finland\u2013an epidemiological study.","volume":"140A","author":"Pakkasj\u00e4rvi","year":"2006","journal-title":"Am J Med Genet A"},{"key":"R31-16-20210126","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/ajmg.a.33493","article-title":"How valid are the rates of Down syndrome internationally? Findings from the International Clearinghouse for Birth Defects Surveillance and Research.","volume":"152A","author":"Leoncini","year":"2010","journal-title":"Am J Med Genet A"},{"key":"R32-16-20210126","article-title":"National Agency for Medicines (Department of safety and drug information) and Social Insurance Institution (Research department): Finnish Statistics on Medicines 2006. 1st ed.","year":"2007"},{"key":"R33-16-20210126","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1471-0528.2010.02531.x","article-title":"Termination of pregnancy for fetal anomaly after 23 weeks of gestation: a European register-based study.","volume":"117","author":"Garne","year":"2010","journal-title":"BJOG"},{"key":"R34-16-20210126","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.reprotox.2009.04.005","article-title":"In vitro and in vivo reproduction toxicology of 12 monoaminergic reuptake inhibitors: possible mechanisms of infrequent cardiovascular anomalies.","volume":"28","author":"Sloot","year":"2009","journal-title":"Reprod Toxicol"},{"key":"R35-16-20210126","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijdevneu.2003.10.002","article-title":"Serotonin and its transporter on proliferation of fetal heart cells.","volume":"21","author":"Sari","year":"2003","journal-title":"Int J Dev Neurosci"},{"key":"R36-16-20210126","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.lfs.2008.10.008","article-title":"Estimation of embryotoxic effect of fluoxetine using embryonic stem cell differentiation system.","volume":"83","author":"Kusakawa","year":"2008","journal-title":"Life Sci"},{"key":"R37-16-20210126","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1067\/mpd.2003.243","article-title":"Temporal variability in birth prevalence of congenital heart defects as recorded by a general birth defects registry.","volume":"142","author":"Bosi","year":"2003","journal-title":"J Pediatr"},{"key":"R38-16-20210126","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1542\/peds.2004-0259","article-title":"A practical clinical approach to diagnosis of fetal alcohol spectrum disorders: clarification of the 1996 institute of medicine criteria.","volume":"115","author":"Hoyme","year":"2005","journal-title":"Pediatrics"},{"key":"R39-16-20210126","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/(SICI)1096-9926(199907)60:1<33::AID-TERA9>3.0.CO;2-X","article-title":"Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. European Medicine and Pregnancy Group.","volume":"60","author":"De Jong van den Berg","year":"1999","journal-title":"Teratology"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0b013e318220edcc","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:27:36Z","timestamp":1786044456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006250-201107000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0b013e318220edcc","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}